Published in AIDS Weekly, February 16th, 2004
All 10 patients in the fourth and final dose group have now received their initial vaccinations. The trial is being conducted at the University of Colorado Health Sciences Center with sponsorship from the National Institutes of Health (NIH).
The phase I/II trial is a double blind, placebo-controlled, dose-escalation study and includes four dose groups of 10 patients each for a total of 40 patients. The primary objective of this study is to determine the safety of the EP HIV-1090 vaccine. The...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.